Clinical Trials Logo

Clinical Trial Summary

Rationale: Lung cancer is the most commonly diagnosed cancer worldwide and is the most frequent cause of cancer death. Accurate staging is important because it directs treatment and prognosis. Mediastinal staging can be done by both EBUS-TBNA and EUS-FNA. These two techniques have a complementary diagnostic range and the combined procedure is suited for assessment of almost the entire mediastinum. In practice, when mediastinal tissue staging is indicated, endoscopists often perform either an EBUS or an EUS investigation (instead of the combined procedure). Second, frequently only one or two, by imaging suspected lymph node stations, are sampled (ie. targeted approach).

Objectives: main and secondary:

1. Complete endosonographic (combined endobronchial and esophageal) staging using a single EBUS scope improves locoregional staging (N2, N3, T4) versus EBUS staging alone.

2. Systematic mediastinal staging results in improved locoregional staging compared to PET-CT directed assessment of the mediastinum (ie targeted approach).

Study population: Patients with potentially operable and resectable NSCLC are eligible if there is an indication for mediastinal nodal sampling. Patients have an indication for EBUS-TBNA.

Intervention: Patients will undergo an EBUS investigation followed by EUS-B in the same session. During this single scope procedure, lymph nodes that are suspected on prior CT-PET imaging and on subsequent ultrasound are sampled.

Main study endpoint: The main study parameter is the sensitivity for locoregional disease (N2, N3, T4 disease) of complete endosonographic staging (by EBUS-TBNA and EUS-B-FNA) in comparison with EBUS staging alone.


Clinical Trial Description

n/a


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02014324
Study type Observational [Patient Registry]
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact
Status Completed
Phase N/A
Start date May 2013
Completion date October 2014

See also
  Status Clinical Trial Phase
Completed NCT01204099 - Study of PX-866 and Docetaxel in Solid Tumors Phase 1/Phase 2
Recruiting NCT04083599 - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors Phase 1/Phase 2
Completed NCT00148798 - Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) Phase 3
Recruiting NCT06026410 - KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Phase 1
Completed NCT02988817 - Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT01005797 - Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Phase 1
Recruiting NCT00637910 - Tarceva Italian Lung Optimization tRial Phase 3
Active, not recruiting NCT03447678 - Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. Phase 2
Completed NCT02456246 - Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT N/A
Terminated NCT01741155 - Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) Phase 2
Completed NCT01594398 - Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer Phase 1
Completed NCT01323062 - Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects Phase 1
Active, not recruiting NCT04772989 - A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies Phase 1
Completed NCT01702844 - Single Arm on the Tolerability of Weekly Nab-paclitaxel Phase 2
Completed NCT00492206 - Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC Phase 2
Completed NCT00820417 - Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib Phase 1
Completed NCT02639026 - Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Phase 1
Completed NCT01282437 - Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC Phase 3
Active, not recruiting NCT04721015 - Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors Phase 1
Not yet recruiting NCT05473156 - A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies Phase 1/Phase 2